8-K: Voyager Therapeutics Adjusts ALS Program, Delays IND Filing for VY9323

Voyager Therapeutics is shifting its focus in its ALS program, leading to a delay in the planned IND filing for VY9323.

Summary

• Voyager Therapeutics is reassessing the payload for its SOD1 ALS Program due to emerging data from non-human primate studies.
• The company no longer anticipates filing an IND application or a Canadian clinical trial application for VY9323 in mid-2025.
• The decision does not affect other gene therapy programs with Neurocrine Biosciences and Novartis.
• Voyager still expects IND filings in 2025 from Neurocrine for Parkinson's disease and Friedreich's ataxia programs.
• The company also anticipates filing an IND in 2026 for VY1706, its tau silencing gene therapy program.
• Voyager estimates its cash runway will extend into mid-2027, based on current plans and expected reimbursements and interest income.

Sentiment

Score: 4

Explanation: The news of the delayed IND filing is a setback, but the company's other programs are progressing, and the cash runway extends into mid-2027, resulting in a moderately negative sentiment.

Positives

• The decision to reassess the payload for the SOD1 ALS Program is proactive, based on emerging data.
• The delay in the VY9323 IND filing does not impact other gene therapy programs with Neurocrine and Novartis.
• The company's cash runway is estimated to extend into mid-2027.
• VY1706, the lead development candidate for its tau silencing gene therapy program, has achieved desired activity levels and been well-tolerated in preclinical studies.

Negatives

• The SOD1 ALS Program requires reassessment of the payload.
• The IND filing for VY9323 is delayed.
• The company's estimates regarding its cash runway are based on assumptions that may prove to be wrong.

Risks

• The company's estimates regarding its cash runway are based on assumptions that may prove to be wrong.
• The expectations and decisions of regulatory authorities could impact the company's plans.
• The timing, initiation, conduct and outcomes of the company's preclinical and clinical trials are subject to risks and uncertainties.
• The sufficiency of the company's cash resources to fund its operations and pursue its corporate objectives is a risk.

Future Outlook

Voyager Therapeutics plans to assess alternate payloads for its SOD1 ALS Program and continues to expect IND filings in 2025 from Neurocrine Biosciences for Parkinson's disease and Friedreich's ataxia programs, as well as an IND filing in 2026 for VY1706.

Industry Context

The gene therapy field is highly competitive, and setbacks in clinical development are not uncommon; Voyager's experience highlights the challenges and risks inherent in developing novel therapies for complex diseases like ALS.

Comparison to Industry Standards

• Other gene therapy companies, such as Sarepta Therapeutics and Biogen, have also faced challenges in their clinical programs, including delays and setbacks.
• The estimated cash runway into mid-2027 is comparable to other biotech companies of similar size and stage of development.
• Voyager's collaborations with Neurocrine and Novartis are similar to other partnerships in the gene therapy space, where companies often collaborate to share expertise and resources.

Stakeholder Impact

• Shareholders may react negatively to the delay in the VY9323 IND filing.
• Patients with ALS may be disappointed by the delay in the development of a potential treatment.
• Employees working on the SOD1 ALS Program may be affected by the reassessment of the payload.

Next Steps

• Voyager Therapeutics will assess alternate payloads for its SOD1 ALS Program.
• The company will continue to advance its other gene therapy programs with Neurocrine Biosciences and Novartis.
• Voyager expects IND filings in 2025 from Neurocrine for Parkinson's disease and Friedreich's ataxia programs.
• The company anticipates filing an IND in 2026 for VY1706, its tau silencing gene therapy program.

Key Dates

Keywords

Voyager Therapeutics, SOD1 ALS Program, VY9323, IND filing, Gene therapy, Neurocrine Biosciences, Parkinson's disease, Friedreich's ataxia, VY1706, Tau silencing, Cash runway